Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2947676 | 0.96 | PPARD (0.63) | PPARDPPARA | |
| SCHEMBL2949790 | 0.96 | PPARD (0.63) | PPARDPPARA | |
| SCHEMBL2947074 | 0.96 | PPARD (0.67) | PPARDPPARA | |
| SCHEMBL2940591 | 0.92 | PPARD (0.59) | PPARDPPARA | |
| SCHEMBL2948339 | 0.92 | PPARD (0.68) | PPARDPPARA | |
| SCHEMBL2942679 | 0.92 | PPARD (0.61) | PPARDPPARA | |
| SCHEMBL2949329 | 0.89 | PPARD (0.64) | PPARDPPARA | |
| SCHEMBL2942325 | 0.88 | PPARD (0.59) | PPARDPPARA | |
| SCHEMBL2950560 | 0.88 | PPARD (0.66) | PPARDPPARA | |
| SCHEMBL2944587 | 0.88 | PPARD (0.66) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750032-B2 | Compounds and compositions as PPAR modulators | IRM LLC (BM) | 2010-07-06 | — | — | US | claimed |
| US-20090137591-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | claimed |
| EP-1843763-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM, LLC (BM) | 2007-10-17 | — | — | EP | claimed |
| WO-2006084176-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2006-08-10 | — | — | WO | claimed |
| US-7750032-B2 | Compounds and compositions as PPAR modulators | IRM LLC (BM) | 2010-07-06 | — | — | US | disclosed |
| US-7750032-B2 | Compounds and compositions as PPAR modulators | IRM LLC (BM) | 2010-07-06 | — | — | US | disclosed |
| US-7750032-B2 | Compounds and compositions as PPAR modulators | IRM LLC (BM) | 2010-07-06 | — | — | US | disclosed |
| US-20090137591-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| EP-1843763-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM, LLC (BM) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006084176-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137591-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | PPARG, PPARD, PPARA | PPARD 2/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.